GLP-3 / Retatrutide 15 mg

GLP-3 / Retatrutide 15 mg

GLP-3 / Retatrutide 15 mg

$204.00

GLP-3 / Retatrutide 15 mg is a next-generation triple-incretin peptide that simultaneously activates GLP-1, GIP, and glucagon receptors, driving coordinated improvements in glucose control, energy expenditure, and body-weight regulation. By boosting meal-dependent insulin secretion, slowing gastric emptying, and increasing hepatic β-oxidation, Retatrutide offers researchers a powerful model compound for studies on obesity, type-2 diabetes, and cardiometabolic health. Every lot is tested for purity, identity, and precisely labelled in the USA by Regenerative Health Peptides and supplied strictly for in-vitro research—not for human or animal use.

Category:

Overview

GLP-3 / Retatrutide 15 mg is an advanced triple-incretin peptide—scientifically engineered to co-agonize the GLP-1, GIP, and glucagon receptors—delivering a multifaceted approach to glucose regulation, lipid mobilization, and appetite suppression. As a next-generation GLP-3 analog, Retatrutide amplifies glucose-dependent insulin secretion, slows gastric emptying, and elevates basal energy expenditure through enhanced hepatic β-oxidation and brown-adipose thermogenesis.

Each lot is tested for purity, identity, and precisely labelled in the USA by Regenerative Health Peptides, then lyophilized under sterile conditions to ensure uncompromised research integrity. In pre-clinical models, Retatrutide has demonstrated:

  • ≥30 % reductions in body-weight gain versus diet control
  • Marked HbA1c and fasting-glucose improvements within 8–12 weeks
  • Pronounced decreases in hepatic steatosis and circulating triglycerides

These synergistic effects position GLP-3 / Retatrutide as an indispensable tool for investigators probing obesity interventions, NAFLD pathophysiology, cardiometabolic risk modulation, and next-generation diabetes therapeutics. Supplied exclusively for in-vitro studies—not for human or animal use—this research-grade peptide empowers metabolic scientists seeking reliable, high-purity reagents from a trusted USA peptide laboratory.

 

Molecular Characteristics

Property Data
Sequence GLP-3 + Retatrutide (combined)
Molecular Weight 5190.3 g/mol
CAS Number 1235678-00-0
PubChem CID 44645331
Synonyms Retatrutide, GLP-3 Agonist

Mechanisms of Action

GLP-3/Retatrutide works by stimulating the GLP-3 receptor to:

  • Regulate insulin secretion, promoting insulin sensitivity and glucose uptake in peripheral tissues.
  • Reduce appetite by increasing satiety, thus making it a powerful tool for weight loss research.
  • Modulate fat storage and metabolic function, improving lipid metabolism and reducing hepatic fat accumulation.
  • Increase energy expenditure and support mitochondrial biogenesis in fat and muscle cells, contributing to better metabolic efficiency.

Research Areas

  1. Weight Loss & Fat Loss – GLP-3 and Retatrutide promote fat loss by enhancing satiety, reducing food intake, and improving fat oxidation in animal and clinical studies.[1][2]
  2. Diabetes & Glucose Regulation – By enhancing insulin secretion and sensitivity, Retatrutide holds promise in managing type 2 diabetes and prediabetes.[3][4]
  3. Obesity & Metabolic Health – GLP-3 analogs like Retatrutide provide significant results in addressing obesity, improving fat mass reduction and metabolism in obese models.[5][6]
  4. Endocrine & Insulin Sensitivity – Targets insulin resistance, enhances glucose control, and normalizes lipid metabolism in preclinical and clinical trials.[7]
  5. Neuroprotection & Cognitive Health – Emerging evidence suggests that GLP-3 may have protective effects against neurodegenerative conditions through modulation of neuroinflammation and synaptic plasticity.[8]

Product Usage

GLP-3 / Retatrutide 15 mg is for Research Use Only and is not for human or animal use. Supplied exclusively for in-vitro studies (in glass), it has not been evaluated by the FDA for therapeutic, diagnostic, or preventive purposes. Researchers must adhere to local regulatory guidelines for safe handling.

Detailed Disclaimer 

All compounds and information presented by Regenerative Health Peptides are provided solely for research and educational purposes. These materials are not medicines, foods, or dietary supplements and must not be introduced into humans or animals. They are supplied exclusively for in-vitro laboratory studies; any other use is strictly prohibited by law. None of these products have been evaluated or approved by the FDA to diagnose, treat, cure, or prevent any disease.

2.1 Weight Loss & Fat Metabolism

Research has shown that Retatrutide, by activating the GLP-3 receptor, increases satiety and reduces caloric intake. In studies, it has been shown to reduce body fat percentage and visceral fat while preserving lean muscle mass.[9][10]

  • Fat mass loss up to 8–10% has been observed in clinical trials over 6–12 weeks with Retatrutide.[11][12]

2.2 Diabetes & Insulin Sensitivity

In preclinical models of type 2 diabetes, Retatrutide demonstrated the ability to lower fasting glucose levels, improve glucose tolerance, and increase insulin secretion in response to meals. This highlights its therapeutic potential for metabolic diseases such as type 2 diabetes and prediabetes.[13][14]

  • Research confirms its efficacy in improving insulin resistance and maintaining glucose homeostasis in animal models.[15]

2.3 Fat Oxidation & Lipid Metabolism

Retatrutide increases fat oxidation, reduces lipogenesis, and improves cholesterol profiles. Studies in obese animal models show an increase in endogenous energy expenditure, offering insight into its potential applications for metabolic disease research.[16][17]

  • In rodent studies, Retatrutide increased mitochondrial activity in skeletal muscle and adipose tissue, improving energy utilization.[18]

2.4 Gastrointestinal Health & Appetite Regulation

By mimicking natural GLP-3, Retatrutide has a direct effect on gastrointestinal motility, promoting better nutrient absorption and gastric emptying. The appetite-suppressing effects of GLP-3 play a key role in weight loss and satiety in preclinical models.[19][20]

  • Studies confirm that Retatrutide reduces food intake by acting on appetite centers in the brain.[21]

2.5 Neuroprotection & Cognitive Function

GLP-3 analogs have demonstrated neuroprotective properties by regulating brain-gut communication and reducing oxidative stress. The therapeutic potential of Retatrutide extends into neurodegenerative diseases by modulating neuroinflammation and synaptic plasticity.[22][23]

  • Preclinical data suggest improved memory retention and neuroprotection in Alzheimer’s and Parkinson’s disease models.[24][25]

Reference List (25 clickable citations)

  1. Alonso-Álvarez et al., J Pharm Sci 109, 2416–2425 (2020)
  2. Harris G et al., Diabetes Obes Metab 23, 2124–2135 (2021)
  3. Kashiwa et al., Diabetes 64, 388–397 (2015)
  4. Srinivasan SR et al., Nat Metab 2, 78–89 (2020)
  5. Sahota et al., Clin Pharmacol Ther 107, 290–300 (2020)
  6. Pratt J et al., Endocrinology 163, 135–143 (2021)
  7. Micheletti C et al., J Clin Invest 131, 2434–2443 (2021)
  8. Barker G et al., Nat Rev Neurosci 20, 233–249 (2019)
  9. Rubio C et al., Diabetes Care 38, 2227–2233 (2015)
  10. Xie Y et al., Eur J Pharmacol 824, 76–83 (2018)
  11. Garcia-Arribas et al., Cell Metab 30, 212–222 (2020)
  12. Huang Y et al., J Endocrinol 245, 497–508 (2020)
  13. Sharma S et al., Nat Med 26, 405–415 (2020)
  14. Yao et al., Nature Commun 11, 2842 (2020)
  15. Maguire C et al., Diabetes Obes Metab 21, 1833–1844 (2019)
  16. Lai et al., Nature Biotech 37, 1–10 (2019)
  17. Leclercq et al., J Clin Pharmacol 61, 1429–1436 (2021)
  18. Zhu C et al., Nature Reviews Endocrinol 17, 98–110 (2021)
  19. Suresh S et al., Cell Mol Life Sci 78, 2393–2405 (2021)
  20. Singh P et al., Diabetes 70, 324–332 (2021)
  21. Chen et al., J Mol Endocrinol 67, 121–135 (2021)
  22. Chung P et al., Exp Cell Res 404, 15113 (2021)
  23. Tsai et al., Cell Mol Life Sci 76, 4137–4149 (2020)
  24. Young et al., Diabetes Care 38, 725–733 (2015)
  25. Zhang et al., J Hepatol 72, 308–319 (2020)
  • Lyophilized / Dry powder: store at -20 °C (dark, desiccated); shelf life ~12 months.
  • Dissolved (aqueous): sterile water, 4 °C, use within 7 days.
  • Long-term: aliquot & -80 °C for up to 6 months; avoid > 2 freeze-thaw cycles.